Comparison 3. Artzal versus Hylan G‐F 20 (Also see Hylan G‐F 20 versus hyaluronan, NRD‐101 versus Artz, SLM‐10 versus Artz).

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Pain on weight bearing (0‐100 mm VAS)	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
1.1 1 to 4 weeks post‐injection	1	176	Mean Difference (IV, Fixed, 95% CI)	‐1.0 [‐8.41, 6.41]
1.2 5 to 13 weeks post‐injection	1	176	Mean Difference (IV, Fixed, 95% CI)	1.0 [‐7.83, 9.83]
1.3 14 to 26 weeks post‐injection	1	176	Mean Difference (IV, Fixed, 95% CI)	5.0 [‐4.98, 14.98]
2 Lequesne Index (0‐24)	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
2.1 1 to 4 weeks post‐injection	0	0	Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
2.2 5 to 13 weeks post‐injection	0	0	Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
2.3 14 to 26 weeks post‐injection	1	180	Mean Difference (IV, Fixed, 95% CI)	1.0 [‐0.37, 2.37]
3 Number of clinical failures	1		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
3.1 14 to 26 weeks post‐injection	1	176	Risk Ratio (M‐H, Fixed, 95% CI)	0.32 [0.07, 1.54]
3.2 45 to 52 weeks post‐injection	1	136	Risk Ratio (M‐H, Fixed, 95% CI)	0.86 [0.58, 1.28]
4 Number of survivors (patients not requiring additional treatment for study knee) (45 to 52 weeks post‐injectio	1		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
5 Safety: number of patients withdrawn due to adverse events (45 to 52 weeks post‐injection)	1		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
6 Safety: number of adverse events related to treatment (45 to 52 weeks post‐ injection)	1		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
7 Safety: number of patients reporting adverse events (45 to 52 weeks post‐ injection)	1		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only